CONSUN PHARMAC.GR.HD -10 (C1P) - Total Liabilities
Based on the latest financial reports, CONSUN PHARMAC.GR.HD -10 (C1P) has total liabilities worth €1.57 Billion EUR (≈ $1.84 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of CONSUN PHARMAC.GR.HD -10 to track the company's year-over-year net asset growth rate.
CONSUN PHARMAC.GR.HD -10 - Total Liabilities Trend (2021–2025)
This chart illustrates how CONSUN PHARMAC.GR.HD -10's total liabilities have evolved over time, based on quarterly financial data. See C1P cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CONSUN PHARMAC.GR.HD -10 Competitors by Total Liabilities
The table below lists competitors of CONSUN PHARMAC.GR.HD -10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ardent Health Partners, Inc.
NYSE:ARDT
|
USA | $3.52 Billion |
|
Tokai Carbon Korea Co. Ltd
KQ:064760
|
Korea | ₩40.75 Billion |
|
Datang Telecom Technology Co Ltd
SHG:600198
|
China | CN¥2.26 Billion |
|
Jiangsu Yunyi Electric
SHE:300304
|
China | CN¥1.17 Billion |
|
NCAB Group
ST:NCAB
|
Sweden | Skr2.08 Billion |
|
Hefei Metalforming Mach Tool
SHG:603011
|
China | CN¥2.50 Billion |
|
Navigator Holdings Ltd
NYSE:NVGS
|
USA | $1.03 Billion |
|
Asana Inc
NYSE:ASAN
|
USA | $652.07 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down CONSUN PHARMAC.GR.HD -10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of CONSUN PHARMAC.GR.HD -10.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CONSUN PHARMAC.GR.HD -10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CONSUN PHARMAC.GR.HD -10 (2021–2025)
The table below shows the annual total liabilities of CONSUN PHARMAC.GR.HD -10 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.57 Billion ≈ $1.84 Billion |
+7.68% |
| 2024-12-31 | €1.46 Billion ≈ $1.71 Billion |
-8.13% |
| 2023-12-31 | €1.59 Billion ≈ $1.86 Billion |
+9.35% |
| 2022-12-31 | €1.45 Billion ≈ $1.70 Billion |
+0.10% |
| 2021-12-31 | €1.45 Billion ≈ $1.70 Billion |
-- |
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney… Read more